Beta Bionics (NASDAQ:BBNX) Releases Earnings Results, Beats Expectations By $0.01 EPS

Beta Bionics (NASDAQ:BBNX) posted its quarterly earnings results on Tuesday. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.01, FiscalAI reports. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The firm had revenue of $35.51 million for the quarter.

Here are the key takeaways from Beta Bionics’ conference call:

• Q3 net sales reached a record $35.5 million, up approximately 30% year over year, driven by new patient starts and recurring pharmacy-channel supply revenue. Gross margin rose to 57.3% year over year, despite unfavorable distributor inventory mix.
• FDA clearance for the Mint patch pump remains the company’s central catalyst, with full U.S. commercialization expected in Q1 2027. Management expects Mint coverage for about 40% of U.S. lives at launch and roughly 50% by year-end 2027, while targeting at least 1.5 million units of production capacity in 2027.
• Beta Bionics raised approximately $161 million in net proceeds, ending the quarter with about $374 million in cash, equivalents and investments. The company said the funds will support Mint manufacturing, commercialization and pipeline investments.
• Full-year 2026 revenue guidance was raised at the low end to $124 million-$126 million, reflecting lower-than-expected deferrals ahead of Mint’s launch. Management expects the deferred revenue to be more than recovered in 2027.
• The FDA requested withdrawal and resubmission of the 3D Intelligence 510(k), citing additional questions about validation of the simulator rather than concerns with the algorithm itself. Beta Bionics plans to resubmit in mid-Q4 2026, but now expects a U.S. launch around mid-2027, and Mint’s gross margin is expected to be dilutive in 2027.

Beta Bionics Price Performance

BBNX stock opened at $17.85 on Thursday. The company’s 50 day simple moving average is $19.21 and its 200-day simple moving average is $14.90. The firm has a market capitalization of $803.07 million, a PE ratio of -10.82 and a beta of 3.39. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71.

Analyst Upgrades and Downgrades

BBNX has been the topic of several research analyst reports. UBS Group reissued a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research note on Tuesday, September 15th. William Blair began coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating on the stock. Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Wells Fargo & Company started coverage on Beta Bionics in a research report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 price target for the company. Finally, Jefferies Financial Group began coverage on Beta Bionics in a research note on Monday, October 12th. They set a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average price target of $23.69.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results slightly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the expected $0.53 loss, while revenue of $35.51 million topped the roughly $34.7 million consensus estimate. The company also updated its full-year 2026 guidance, though the available reports did not provide the specific changes. Beta Bionics Announces Third-Quarter 2026 Results
• Neutral Sentiment: Insider selling was modest in the latest transaction. Insider Mark Hopman sold 821 shares for approximately $16,420, reducing his direct ownership by 1.48%. The sale may weigh somewhat on sentiment, but he retained more than 54,000 shares. SEC Insider Filing
• Negative Sentiment: Several law firms are publicizing a pending securities class action. The litigation covers investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. Investors have until November 3, 2026, to seek lead-plaintiff status. The unusually large number of notices amplifies legal, reputational, and headline risk for the company. Kaplan Fox Class-Action Notice
• Negative Sentiment: The allegations focus on iLet device safety and FDA compliance. Lawsuit notices allege Beta Bionics failed to disclose a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints. Separately, the company identified execution risks surrounding the commercial launch of its Mint patch pump. If regulators impose additional requirements or product issues delay commercialization, growth expectations and valuation could face further pressure. The allegations remain unproven. Beta Bionics FDA and Class-Action Report

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. This represents a 4.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the sale, the insider owned 169,628 shares in the company, valued at approximately $3,241,591.08. This trade represents a 2.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 99,293 shares of company stock worth $1,936,901. 5.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently made changes to their positions in BBNX. Squarepoint Ops LLC acquired a new position in Beta Bionics in the 2nd quarter valued at about $2,524,000. Bank of America Corp DE acquired a new position in shares of Beta Bionics in the second quarter valued at approximately $8,566,000. Man Group plc purchased a new stake in Beta Bionics in the 2nd quarter worth approximately $419,000. Legal & General Group Plc purchased a new stake in Beta Bionics in the 2nd quarter worth approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Beta Bionics in the 2nd quarter valued at $172,000.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.